A detailed history of Concourse Financial Group Securities, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 100 shares of ALT stock, worth $825. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 100 -0.0%
Holding current value
$825
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$3.45 - $5.97 $345 - $597
100 New
100 $0
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

BUY
$8.74 - $16.45 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022

BUY
$10.67 - $22.41 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022

BUY
$3.94 - $11.77 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022

BUY
$5.9 - $9.45 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022

SELL
$8.69 - $12.48 $1,738 - $2,496
-200 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$12.71 - $24.31 $2,542 - $4,862
200 New
200 $3,000
Q4 2020

Feb 02, 2021

BUY
$7.84 - $14.22 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020

BUY
$9.93 - $33.26 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020

BUY
$2.9 - $10.71 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020

BUY
$1.69 - $3.8 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020

BUY
$1.53 - $2.15 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019

BUY
$1.95 - $2.66 $0 - $0
0 New
0 $0
Q2 2019

Aug 13, 2019

BUY
$2.19 - $3.4 $0 - $0
0 New
0 $0
Q1 2019

May 15, 2019

BUY
$2.54 - $4.54 $0 - $0
0 New
0 $0
Q4 2018

Feb 14, 2019

BUY
$1.72 - $7.24 $0 - $0
0 New
0 $0
Q3 2018

Nov 13, 2018

BUY
$4.27 - $26.23 $0 - $0
0 New
0 $0

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.